Nasal Polyps - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Nasal Polyps - Pipeline Review, H2 2018’, provides an overview of the Nasal Polyps pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasal Polyps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasal Polyps and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasal Polyps

- The report reviews pipeline therapeutics for Nasal Polyps by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Nasal Polyps therapeutics and enlists all their major and minor projects

- The report assesses Nasal Polyps therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Nasal Polyps

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nasal Polyps

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nasal Polyps pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

Kyowa Hakko Kirin Co Ltd

Pfizer Inc

Regeneron Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

Kyowa Hakko Kirin Co Ltd

Pfizer Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasal Polyps (Nasal Polyposis) – Overview

Nasal Polyps (Nasal Polyposis) – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasal Polyps (Nasal Polyposis) – Overview

Nasal Polyps (Nasal Polyposis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nasal Polyps (Nasal Polyposis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasal Polyps (Nasal Polyposis) – Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

Kyowa Hakko Kirin Co Ltd

Pfizer Inc

Regeneron Pharmaceuticals Inc

Nasal Polyps (Nasal Polyposis) – Drug Profiles

ACT-774312 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-201 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06817024 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasal Polyps (Nasal Polyposis) – Dormant Projects

Nasal Polyps (Nasal Polyposis) – Discontinued Products

Nasal Polyps (Nasal Polyposis) – Product Development Milestones

Featured News & Press Releases

Jun 27, 2017: GSK Starts Phase III Study with Mepolizumab in Patients with Nasal Polyps

Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab

Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2018

Number of Products under Development by Companies, H2 2018

Products ...

List of Tables

Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Nasal Polyps (Nasal Polyposis) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Nasal Polyps (Nasal Polyposis) – Pipeline by GlaxoSmithKline Plc, H2 2018

Nasal Polyps (Nasal Polyposis) – Pipeline by Idorsia Pharmaceutical Ltd, H2 2018

Nasal Polyps (Nasal Polyposis) – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Nasal Polyps (Nasal Polyposis) – Pipeline by Pfizer Inc, H2 2018

Nasal Polyps (Nasal Polyposis) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Nasal Polyps (Nasal Polyposis) – Dormant Projects, H2 2018

Nasal Polyps (Nasal Polyposis) – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Figures

Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports